Pharmafile Logo
Pharmafocus logo
Advanced Search

androgel

Showing 5 posts of 5 posts found.

abbvie_0

Chicago Judge overturns $140 million AbbVie AndroGel verdict

August 13, 2018
Sales and Marketing AbbVie, Litigation, androgel, legal, testosterone

A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc. The verdict, which ruled in …

News
abbvie_0

AbbVie ordered to pay $448m over generic delays

July 2, 2018
Sales and Marketing AbbVie, FTC, androgel, besins, branded generics, pharma

A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham …

News
abbvie_0

Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack

March 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Endo, GSK, androgel, heart attack, pharma

Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of …

News
androgel

AbbVie hit with $140m fine over fraudulent marketing of Androgel

October 6, 2017
Medical Communications, Sales and Marketing AbbVie, androgel, biotech, drugs, pharma, pharmaceutical

AbbVie has been stung with a $140 million damages award to a man that suffered a heart attack after using …

News
FTC building

Federal Trade Commission sues AbbVie and Teva

September 9, 2014
Manufacturing and Production, Sales and Marketing AbbVie, FTC, Teva, androgel, federal trade commission

Authorities in the US claim that AbbVie and Teva filed ‘sham’ lawsuits in a complicated pay-to-delay case for generic forms …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024